MARKET

CELC

CELC

Celcuity Inc
NASDAQ
11.14
-0.08
-0.71%
Pre Market: 11.28 +0.14 +1.26% 06:07 05/01 EDT
OPEN
11.10
PREV CLOSE
11.22
HIGH
11.40
LOW
10.67
VOLUME
265
TURNOVER
0
52 WEEK HIGH
19.77
52 WEEK LOW
7.58
MARKET CAP
421.53M
P/E (TTM)
-3.9315
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CELC last week (0421-0425)?
Weekly Report · 3d ago
Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 04/22 12:08
Weekly Report: what happened at CELC last week (0414-0418)?
Weekly Report · 04/21 11:38
Weekly Report: what happened at CELC last week (0407-0411)?
Weekly Report · 04/14 11:26
Celcuity Price Target Maintained With a $29.00/Share by Needham
Dow Jones · 04/11 10:43
Needham Reiterates Buy on Celcuity, Maintains $29 Price Target
Benzinga · 04/11 10:34
Celcuity’s Strong Position and FDA Breakthrough Designation Drive Buy Rating
TipRanks · 04/10 19:55
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 04/08 12:35
More
About CELC
More
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Recently
Symbol
Price
%Change

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.